The Chinese drug administration approved China Resources Double-Crane Pharmaceutical's (SHA:600062) supplementary application to increase the specifications of sugammadex sodium injection, according to a Shanghai Stock Exchange filing on Wednesday.
The specification of the drug will be raised to 5 milliliters:500 milligrams.
The drug is used for the reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults and for the reversal of rocuronium-induced blockade in children and adolescents, the pharmaceutical company said.
A new drug approval number that will be valid for 12 months will be issued.